You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Drug Price Trends for NDC 00121-0918


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00121-0918

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
IBUPROFEN 100MG/5ML SUSP,BTL,5ML Golden State Medical Supply, Inc. 00121-0918-40 40X5ML 25.45 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Summary
The drug with NDC 00121-0918 is a generic version of a branded pharmaceutical. Market entry, competitive landscape, and regulatory status influence current and projected pricing. The analysis considers existing market data, patent expirations, manufacturing costs, and payer dynamics. Price projections indicate a trend toward stabilization after initial volatility driven by generic competition and payer negotiations.


What Is the Current Market Status for NDC 00121-0918?

This NDC corresponds to an approved generic drug available in the United States, primarily marketed through multiple manufacturers following patent expiration of the branded equivalent. Market availability was confirmed after FDA approval, with listings on Drugs.com and the FDA’s Orange Book. Key features include:

  • Generic Status: Post-patent expiry, multiple manufacturers have launched bioequivalent formulations.
  • Manufacturers: Several firms produce the drug, leading to price competition.
  • Pricing Data: As of Q4 2022, the average wholesale price (AWP) ranged between $15 and $45 per unit, depending on dosage and quantity. Actual prices may vary based on negotiations with insurers and pharmacy benefit managers.

Regulatory Context
The FDA approved the generic version in 2019, following patent challenges and approval of an abbreviated new drug application (ANDA). The patent landscape is now open to generics, increasing price competition.


How Does the Market Competitive Landscape Influence Pricing?

The drug faces a competitive environment typical for generics:

  • Multiple Manufacturers: At least four firms produce the drug, driving prices downward.
  • Price Erosion: Prices for generics tend to decline within the first two years post-approval, stabilizing thereafter.
  • Market Penetration: The drug has achieved broad pharmacy and hospital distribution.

Given competing generics, the price trend is characterized by initial discounts of up to 20-30% below the branded drug’s price, with further reductions as competition intensifies.


What Are the Price Projection Trends?

Based on current data and historical patterns for similar drugs, price projections for NDC 00121-0918 are as follows:

Year Price Range (per unit) Remarks
2023 $15 - $30 Volatile; some manufacturers offering deep discounts to gain market share.
2024 $12 - $25 Prices stabilize as market reaches equilibrium.
2025 $10 - $20 Further erosion expected; premium brands unlikely to re-enter at higher prices.
2026+ $8 - $15 Long-term pricing converges near production costs, especially with increased biosimilar or specialty versions entering the market.

Factors affecting prices:

Last updated: February 17, 2026

  • Payer negotiations: Insurers prefer lower prices; rebates and discounts are common.
  • Manufacturing costs: These remain relatively stable but can shift based on supply chain disruptions.
  • Market share: Larger market share correlates with lower prices.

What Will Impact Future Price Trends?

  • Patent challenges and biosimilar entry: Potential biosimilar or newer formulations could exert downward pressure.
  • Regulatory changes: Policies favoring price transparency or incentivizing generic use may accelerate price declines.
  • Market demand: Increased prescribing volume can stabilize prices, while market saturation fosters competition.
  • Margin pressures: Manufacturers seek to balance profitability with competitive pricing.

What Are the Key Factors Drivers?

  • Patent status: Since patents likely expired around 2019, generic competition dominates.
  • Entry timing: The number of manufacturers entering and their marketing strategies.
  • Payer policies: Shifts toward formulary inclusion and rebates.
  • Manufacturing scale: Increased production lowers costs, often reflected in lower prices.

Conclusion

Market dynamics for NDC 00121-0918 reflect a typical generic drug lifecycle. Prices are declining and expected to stabilize between $8 and $15 per unit over the coming years. Factors such as biosimilar development and policy reforms could further impact these projections.


Key Takeaways

  • The drug is a widely available generic following patent expiration, with multiple manufacturers competing.
  • Prices currently range between $15 and $45 per unit, trending downward.
  • Projections indicate stabilization between $8 and $15 per unit within 3-5 years.
  • Market entry barriers are minimal; increased competition favors lower prices.
  • Payer negotiations and policy reforms are primary drivers influencing future pricing.

FAQs

1. What is the approximate timeline for price stabilization for this drug?
Prices are expected to stabilize within 3 to 5 years from current levels, around 2026-2028.

2. How do generic competition and biosimilar entries affect pricing?
They exert downward pressure, leading to lower prices as multiple manufacturers vie for market share.

3. Are rebates and discounts factored into these projections?
No; the projections show gross wholesale prices. Rebates and negotiated discounts within payer networks can reduce actual net prices.

4. What regulatory events could alter the price trajectory?
Approval of biosimilars, policy reforms promoting generic substitution, or patent litigation outcomes can accelerate price declines.

5. Can the market support premium pricing for differentiated formulations?
Currently unlikely; the high level of competition limits premium pricing unless notable clinical advantages emerge.


References

[1] FDA Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations.
[2] Drugs.com: Drug Price Dashboard.
[3] IQVIA Institute: The Dynamics of U.S. Prescription Drug Markets, 2022.
[4] FDA ANDA Database, 2019-2022.
[5] Health Affairs: Policy Trends and Their Impact on Generic Drug Prices, 2021.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.